Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

CXA-201 (ceftolozane/tazobactam)

Gram-negative CXA-201

for cUTI (complicated urinary tract infection)

CXA-201 (ceftolozane/tazobactam), which is being developed as a first-line intravenous therapy for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, advanced into Phase 3 trials in July 2011…

Cubicin
Entereg
Dificid

Upcoming Events

News & Press

15 May

Cubist Announces First Scientific Presentations of Phase 2 Data for CB-5945 in the Treatment of Opioid-Induced Constipation

Phase 3 studies in this indication planned to begin by the end of 2012

LEXINGTON, Mass. -- Cubist Pharmaceuticals today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.

Careers at Cubist

Hernando

Meet Hernando

Senior Medical Director, Clinical Research

Q: What are your basic job responsibilities? Hernando: I am a senior medical director working in clinical research at Cubist,…

Current Opportunities

View our Careers page to see all current opportunities with Cubist.

Community Outreach

Steve Gillman and Sean Muller

Cubist Selects Science Education Award Winner

Cubist, in partnership with the New England Patriots Radio Network, 98.5 The Sports Hub, has selected Sean Muller, a science teacher at Merrimack High School, in Merrimack, New Hampshire, to receive the Cubist Pharmaceuticals Science Education Leadership Award.

Investor Center

Cubist Pharmaceuticals $39.83 -1.19
CBST (NASDAQ) UPD: 4:00 pm

Investor Resources